SCHEMBL6528012

SCHEMBL6528012

Sc1ccc(Oc2ccccn2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 2/20 0.50
LTA4H P09960 1/20 0.50
PDE10A Q9Y233 1/20 0.46
KDM4E B2RXH2 2/20 0.43
HRH3 Q9Y5N1 1/20 0.40
TLR4 O00206 1/20 0.40
TLR2 O60603 1/20 0.40
SCN9A Q15858 1/20 0.40
LMNA P02545 1/20 0.39
CYP1A2 P05177 1/20 0.39
POLB P06746 1/20 0.39
CCR1 P32246 1/20 0.39
CCR5 P51681 1/20 0.39
CCR8 P51685 1/20 0.39
METAP1 P53582 1/20 0.39
BLM P54132 1/20 0.39
HIF1A Q16665 1/20 0.39
DOHH Q9BU89 1/20 0.39
P4HTM Q9NXG6 1/20 0.39
IP6K1 Q92551 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11143982 0.89 PTGS2 (0.57) PTGS2LTA4HPDE10AKDM4EHRH3
SCHEMBL4799330 0.84 PTGS2 (0.50) PTGS2LTA4HPDE10AKDM4EHRH3
SCHEMBL147539 0.83 LOXL2 (0.52) PTGS2LTA4HPDE10AKDM4ETLR4
SCHEMBL29610302 0.83 LOXL2 (0.52) PTGS2LTA4HPDE10AKDM4ETLR4
SCHEMBL5443693 0.81 LTA4H (0.50) PTGS2LTA4HPDE10AKDM4ETLR4
SCHEMBL8510667 0.81 LTA4H (0.50) PTGS2LTA4HPDE10AKDM4ETLR4
SCHEMBL5686657 0.80 LTA4H (0.54) PTGS2LTA4HPDE10AKDM4EHRH3
SCHEMBL10753672 0.80 PTGS2 (0.50) PTGS2LTA4HPDE10AKDM4EHRH3
SCHEMBL568653 0.80 LTA4H (0.50) PTGS2LTA4HPDE10AKDM4EHRH3
SCHEMBL9762783 0.80 PTGS2 (0.50) PTGS2LTA4HPDE10AKDM4EHRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11351168-B1 2,4-disubstituted pyrimidines useful as kinase inhibitors CELGENE CAR LLC (BM) 2022-06-07 US disclosed
EP-3760633-B1 OXAZINO-QUINAZOLINE AND OXAZINO-QUINAZOLINE TYPE COMPOUND, PREPARATION METHOD THEREFOR, AND USES THEREOF BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) 2021-12-15 EP disclosed
WO-2005040112-A1 COMPOUNDS WITH PGD2 ANTAGONIST ACTIVITY OXAGEN LIMITED (GB) 2005-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11351168-B1 2,4-disubstituted pyrimidines useful as kinase inhibitors DCK, CDK2, DTYMK PTGS2 1705/4885LTA4H 3529/4885PDE10A 1957/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.